Results 71 to 80 of about 18,501 (187)

Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

open access: yesInternational Journal of Cancer, Volume 159, Issue 2, Page 389-400, 15 July 2026.
What's new? Effective cervical cancer prevention centers around screening and testing for human papillomavirus (HPV) infection. With birth cohorts of HPV‐vaccinated women now reaching screening‐eligible ages, however, the best means to maintaining cost‐effective cervical cancer screening is unclear.
Tiago M. de Carvalho   +2 more
wiley   +1 more source

Natural history of anal dysplasia in an HIV-infected clinical care cohort: estimates using multi-state Markov modeling.

open access: yesPLoS ONE, 2014
Objectives(1) To model the natural history of anal neoplasia in HIV-infected patients using a 3-state Markov model of anal cancer pathogenesis, adjusting for cytology misclassification; and (2) to estimate the effects of selected time-varying covariates ...
William C Mathews   +4 more
doaj   +1 more source

Cervical Metastasis From Primary Breast Carcinoma: A Case Report and Review of Extragenital Tumors Involving the Uterine Cervix

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Cervical metastases from breast carcinoma should be considered in the differential diagnosis of uterine lesions in patients with prior breast cancer. Re‐biopsy is essential to detect receptor discordance (ER/PR up to 29%) and guide therapy. GCDFP‐15, mammaglobin, and GATA3 confirm mammary origin.
Mario Assenza   +3 more
wiley   +1 more source

HPV negative conversion following Hiporfin PDT for HPV associated HSIL in the female lower reproductive tract

open access: yesScientific Reports
Currently, there is no relevant literature specifically discussing the human papillomavirus (HPV) negative conversion rate following Hiporfin photodynamic therapy (PDT) in HPV-associated high-grade squamous intraepithelial lesion (HSIL) of the female ...
Yu Liu   +4 more
doaj   +1 more source

Predictive factors for the absence of high‐grade intraepithelial lesions in LLETZ specimens following a prior histological diagnosis

open access: yesActa Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 7, Page 1240-1246, July 2026.
About 9.4% of patients with biopsy‐proven high‐grade cervical lesions had ultimately no high‐grade lesion (HGIL) in the excision specimen. The probability of the absence of HGIL was significantly increased in patients with a small lesion, with minor changes or normal colposcopy, and in those with normal cytology or minor abnormalities.
Sophia Assirlikian   +10 more
wiley   +1 more source

Wide-field radiofrequency ablation (RFA) of anal high-grade dysplasia (HSIL) decreases recurrence over targeted ablation

open access: yesPapillomavirus Research, 2018
Background: Recurrence post HSIL ablation is high primarily from development of metachronous HSIL. Trials of hemi-circumferential and circumferential RFA of anal HSIL demonstrated reduced HSIL in treated areas at one year.
Stephen E. Goldstone, M, Justin Im, BAS
doaj   +1 more source

Cost‐effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV‐positive women in cervical cancer screening

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3141-3151, 15 June 2026.
What's new? Persistent infection with high‐risk human papillomavirus (HPV) causes most invasive cervical cancer cases, leading many countries to transition from cytology to primary HPV‐based screening. Despite the benefits, HPV‐based screening may also lead to unnecessary procedures, psychological burden, and strain on healthcare systems.
Kelsi R. Kroon   +2 more
wiley   +1 more source

Health care policy trial of primary human papillomavirus–based cervical screening in Denmark: Comparison of three triage algorithms

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3197-3207, 15 June 2026.
What's new? Primary human papillomavirus (HPV)–based screening has shown superiority to cytology‐based screening in reducing cervical cancer risk in clinical trials. However, the benefit must be balanced with potential overdiagnosis/overtreatment.
Jeppe Bennekou Schroll   +11 more
wiley   +1 more source

Retrospective analysis of cervical screening abnormalities in women with type 3 transformation zone without visible lesions [PDF]

open access: yesPeerJ
Objective Women with abnormal cervical screening but without visible lesions, particularly those with a type 3 transformation zone (TZ3), present a clinical challenge due to the non-visible squamocolumnar junction, increasing the risk of missed high ...
Jing Yang   +5 more
doaj   +2 more sources

Performance of CADM1, MAL and miR124-2 methylation as triage markers for early detection of cervical cancer in self-collected and clinician-collected samples: an exploratory observational study in Papua New Guinea

open access: yesBMJ Open
Objective WHO recommends human papillomavirus (HPV) testing for cervical screening, with triage of high-risk HPV (hrHPV) positive women. However, there are limitations to effective triage for low-resource, high-burden settings, such as Papua New Guinea ...
John Kaldor   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy